Holocene Advisors
MDGL icon

Holocene Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Holocene Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-224,600
Closed -$54.4M – 802
2023
Q1 		$54.4M Buy
+224,600
New +$61.2M 0.27% 124

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Holocene Advisors's MDGL Position: Q2 2026 in Review

Holocene Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 152,924 shares worth $82.1M. The stake represents 0.19% of the portfolio and ranks #147 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in MDGL as recently as Q1 2025.

Holocene Advisors first reported a position in MDGL in Q1 2025 and has held it in 2 quarters since. The position peaked at $129M in Q1 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Holocene Advisors held 152,924 shares of Madrigal Pharmaceuticals worth $82.1M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Holocene Advisors position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.19% of Holocene Advisors's portfolio in Q2 2026, its #147 holding.
  • Holocene Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • Holocene Advisors's Madrigal Pharmaceuticals position peaked at $129M in Q1 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.